BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for Hepatic Encephalopathy: . Drugs 2010;70:1131-48. [DOI: 10.2165/10898630-000000000-00000] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
2 Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol 2014;54:1368-74. [PMID: 24945932 DOI: 10.1002/jcph.348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
3 Venema K. Intestinal fermentation of lactose and prebiotic lactose derivatives, including human milk oligosaccharides. International Dairy Journal 2012;22:123-40. [DOI: 10.1016/j.idairyj.2011.10.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
4 Jia Z, Chen A, Bao F, He M, Gao S, Xu J, Zhang X, Niu P, Wang C. Effect of nisin on microbiome-brain-gut axis neurochemicals by Escherichia coli -induced diarrhea in mice. Microbial Pathogenesis 2018;119:65-71. [DOI: 10.1016/j.micpath.2018.04.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386-1395. [PMID: 25164154 DOI: 10.1111/nmo.12417] [Cited by in Crossref: 122] [Cited by in F6Publishing: 109] [Article Influence: 15.3] [Reference Citation Analysis]
6 Chopra A, Kolla BP, Mansukhani MP, Netzel P, Frye MA. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. General Hospital Psychiatry 2012;34:290-8. [DOI: 10.1016/j.genhosppsych.2011.12.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
7 Allen RG, Lafuse WP, Galley JD, Ali MM, Ahmer BM, Bailey MT. The intestinal microbiota are necessary for stressor-induced enhancement of splenic macrophage microbicidal activity. Brain Behav Immun 2012;26:371-82. [PMID: 22100833 DOI: 10.1016/j.bbi.2011.11.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
8 Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev 2014;:CD003047. [PMID: 24515383 DOI: 10.1002/14651858.CD003047.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yuan LY, Wu YY, Li H. Microbial modulators for treatment of liver failure with endotoxemia: Research progress. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1286-1291 [DOI: 10.11569/wcjd.v21.i14.1286] [Reference Citation Analysis]
10 Chang C, Huang CH, Tseng HJ, Yang FC, Chien RN. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan. J Pers Med 2021;11:478. [PMID: 34071787 DOI: 10.3390/jpm11060478] [Reference Citation Analysis]
11 Feng HW, Hui K, Sun QW, Yu N. Ornithine aspartate combined with naloxone improves cognitive function, prognosis, and neuropeptide levels in patients with hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2014; 22(18): 2612-2616 [DOI: 10.11569/wcjd.v22.i18.2612] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol 2021;75:1452-64. [PMID: 34453966 DOI: 10.1016/j.jhep.2021.08.004] [Reference Citation Analysis]
13 Ames NJ, Ranucci A, Moriyama B, Wallen GR. The Human Microbiome and Understanding the 16S rRNA Gene in Translational Nursing Science. Nurs Res 2017;66:184-97. [PMID: 28252578 DOI: 10.1097/NNR.0000000000000212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
14 Lee HJ, Choi JK, Ryu HS, Choi CH, Kang EH, Park KS, Min YW, Hong KS. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neurogastroenterol Motil 2017;23:9-19. [PMID: 28049862 DOI: 10.5056/jnm16124] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ahuja NK, Ally WA, Caldwell SH. Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy? Annals of Hepatology 2014;13:179-86. [DOI: 10.1016/s1665-2681(19)30880-4] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, Eghtesad B, Singh K, Fu X, Dubyak G, McDonald C, Almasan A, Hazen SL, Naga Prasad SV, Dasarathy S. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303:E983-E993. [PMID: 22895779 DOI: 10.1152/ajpendo.00183.2012] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 10.9] [Reference Citation Analysis]
17 Abd-Elsalam S, El-Kalla F, Elwan N, Badawi R, Hawash N, Soliman S, Soliman S, Elkhalawany W, ElSawaf MA, Elfert A. A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. J Clin Gastroenterol. 2019;53:226-230. [PMID: 29668561 DOI: 10.1097/mcg.0000000000001040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
18 Mladenović D, Hrnčić D, Petronijević N, Jevtić G, Radosavljević T, Rašić-Marković A, Puškaš N, Maksić N, Stanojlović O. Finasteride improves motor, EEG, and cellular changes in rat brain in thioacetamide-induced hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2014;307:G931-40. [PMID: 25104500 DOI: 10.1152/ajpgi.00463.2013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
19 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
20 Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541 [PMID: 31293721 DOI: 10.4254/wjh.v11.i6.531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
21 Wijarnpreecha K, Chesdachai S, Thongprayoon C, Jaruvongvanich V, Ungprasert P, Cheungpasitporn W. Association of Helicobacter pylori with the Risk of Hepatic Encephalopathy. Dig Dis Sci. 2017;62:3614-3621. [PMID: 29119412 DOI: 10.1007/s10620-017-4834-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777 [PMID: 22371636 DOI: 10.3748/wjg.v18.i8.767] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
23 Xu R, Chang J. Progress in treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1755-1762 [DOI: 10.11569/wcjd.v23.i11.1755] [Reference Citation Analysis]
24 Le Sueur-Maluf L, Viana MB, Nagaoka MR, Amorim AL, Cardoso AN, Rodrigues BC, Mendes NF, Bittencourt JC, Céspedes IC. Behavioral alterations and Fos protein immunoreactivity in brain regions of bile duct-ligated cirrhotic rats. An Acad Bras Cienc 2015;87:331-493. [PMID: 25714078 DOI: 10.1590/0001-3765201420130262] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Ishikawa M, García-Mateo N, Čusak A, López-Hernández I, Fernández-Martínez M, Müller M, Rüttiger L, Singer W, Löwenheim H, Kosec G, Fujs Š, Martínez-Martínez L, Schimmang T, Petković H, Knipper M, Durán-Alonso MB. Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. Sci Rep 2019;9:2410. [PMID: 30787404 DOI: 10.1038/s41598-019-38634-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
26 Bosoi CR, Parent-Robitaille C, Anderson K, Tremblay M, Rose CF. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology. 2011;53:1995-2002. [PMID: 21384402 DOI: 10.1002/hep.24273] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
27 Ye JF, Ju J. Rifaximin for prevention and treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(7): 1090-1096 [DOI: 10.11569/wcjd.v23.i7.1090] [Reference Citation Analysis]
28 Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. World J Gastroenterol 2012; 18(46): 6693-6700 [PMID: 23239905 DOI: 10.3748/wjg.v18.i46.6693] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
29 DellaVolpe JD, Garavaglia JM, Huang DT. Management of Complications of End-Stage Liver Disease in the Intensive Care Unit. J Intensive Care Med 2016;31:94-103. [PMID: 25223828 DOI: 10.1177/0885066614551144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
30 Dasarathy S, Mookerjee RP, Rackayova V, Rangroo Thrane V, Vairappan B, Ott P, Rose CF. Ammonia toxicity: from head to toe? Metab Brain Dis. 2017;32:529-538. [PMID: 28012068 DOI: 10.1007/s11011-016-9938-3] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 15.7] [Reference Citation Analysis]
31 Holecek M. Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy. Nutrition 2015;31:14-20. [DOI: 10.1016/j.nut.2014.03.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
32 Hung TY, Chen CC, Wang TL, Su CF, Wang RF. Transient hyperammonemia in seizures: a prospective study. Epilepsia. 2011;52:2043-2049. [PMID: 21972984 DOI: 10.1111/j.1528-1167.2011.03279.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
33 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
34 Pazourek J. Rapid HPLC method for monitoring of lactulose production with a high yield. Carbohydr Res 2019;484:107773. [PMID: 31404813 DOI: 10.1016/j.carres.2019.107773] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
36 McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;CD008716. [PMID: 22071855 DOI: 10.1002/14651858.cd008716.pub2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
37 Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013;57:2690-2693. [PMID: 23545528 DOI: 10.1128/aac.00548-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
38 Belavic JM. A new use for Xifaxan. Nurse Pract. 2011;36:8-9. [PMID: 21685772 DOI: 10.1097/01.NPR.0000398828.65237.db] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
40 Ayloo S, Armstrong J, Hurton S, Molinari M. Obesity and liver transplantation. World J Transplant 2015; 5(3): 95-101 [PMID: 26421262 DOI: 10.5500/wjt.v5.i3.95] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
41 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
42 Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43 Suppl 1:37-49. [PMID: 26618924 DOI: 10.1111/apt.13437] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
43 Thackaberry EA. Non-clinical toxicological considerations for pharmaceutical salt selection. Expert Opinion on Drug Metabolism & Toxicology 2012;8:1419-33. [DOI: 10.1517/17425255.2012.717614] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
44 Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014; 12: 1390-7. e2. [PMID: 24365449 DOI: 10.1016/j.cgh.2013.12.021] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 12.9] [Reference Citation Analysis]
45 Bian T, Zhang X, He G, Duan Z, Dong C, Li X, Guo N. Citric acid-loaded W 1 /O/W 2 multiple emulsions efficiently remove colonic ammonia both in vitro and in vivo. Journal of Dispersion Science and Technology 2017;38:1-7. [DOI: 10.1080/01932691.2015.1038750] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Torres-vega MA, Vargas-jerónimo RY, Montiel-martínez AG, Muñoz-fuentes RM, Zamorano-carrillo A, Pastor AR, Palomares LA. Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia. Gene Ther 2015;22:58-64. [DOI: 10.1038/gt.2014.89] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
47 Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. Can J Neurol Sci. 2013;40:768-776. [PMID: 24257215 DOI: 10.1017/s0317167100015870] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
48 Kimer N, Krag A, Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence. 2014;8:331-338. [PMID: 24672227 DOI: 10.2147/PPA.S41565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
49 Coggins CC, Curtiss CP. Assessment and management of delirium: a focus on hepatic encephalopathy. Palliat Support Care 2013;11:341-52. [PMID: 23040331 DOI: 10.1017/S1478951512000600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]